Supplier qualification and audit program in sterile manufacturing are essential to ensure compliance, protect supply continuity, and meet rising regulatory expectations. Without a structured framework, supplier-related issues can cause production delays, increase deviations, and trigger negative audit outcomes. This case study highlights how GMP Bridge helped a mid-sized sterile fill & finish manufacturer in Spain establish a robust supplier qualification and audit program — delivering improved oversight, reduced risks, and long-term sustainability.
A mid-sized sterile fill & finish manufacturer in Spain relied on an expanding supplier network but lacked a structured program for supplier qualification and oversight. This created inconsistent evaluations, delayed approvals, production disruptions, and increasing pressure from clients and regulators to improve supplier management.
GMP Bridge established a structured, risk-based supplier qualification and audit program to strengthen oversight of critical CMOs, laboratories, and service providers while ensuring sustainable GMP compliance.
Mapped all GMP-relevant suppliers and service providers, including CMOs, contract laboratories, and key technical partners.
Applied structured risk-based criteria to identify critical suppliers and prioritize qualification and audit activities.
Conducted multi-day on-site audits simulating FDA Pre-Approval Inspections (PAIs) across both manufacturing sites
Designed a standardized supplier qualification process with defined approval workflows and documentation requirements.
Developed an annual audit plan focusing on high-risk and strategically important suppliers.
Executed remote and on-site supplier audits led by GMP Bridge auditors to evaluate GMP compliance and operational maturity.
Trained internal QA teams in supplier management processes and audit readiness to ensure long-term sustainability of the program.
The supplier qualification and audit program significantly strengthened supply chain governance, improved transparency across the supplier network, and reduced operational and compliance risks.
Established improved oversight and transparency across the entire GMP-relevant supplier network, including CMOs and external laboratories.
Implemented a structured, risk-based qualification and monitoring strategy to focus resources on the most critical suppliers.
Significantly increased audit coverage of high-risk suppliers and outsourced processes, strengthening overall GMP compliance.
Improved supplier oversight reduced production delays, compliance risks, and operational disruptions.
Empowered internal QA teams through training and clear governance structures to sustain and continuously improve the program.